Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
Gilead and Merck discontinued the Phase 3 KEYNOTE-D46/EVOKE-03 study of Trodelvy plus KEYTRUDA in metastatic non-small cell lung cancer. The external Data Monitoring Committee recommended stopping the trial after a pre-specified analysis showed PFS improvement was not statistically significant and the probability of achieving significant OS is unlikely. The safety profile of the combination was consistent with known risks, with no new safety signals identified.
Key figures
- Drug Name
- Trodelvy (sacituzumab govitecan-hziy)
- Phase Of Trial
- Phase 3
- Study name
- KEYNOTE-D46/EVOKE-03
- Patient enrollment
- 620
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.